This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patz, E. F. Articles by Herndon, J. E. Search for Related Content PubMed PubMed Citation Articles by Patz, E. F., Jr Articles by Herndon, J. E., II

Panel of Serum Biomarkers for the Diagnosis of Lung Cancer

Edward F. Patz, Jr, Michael J. Campa, Elizabeth B. Gottlin, Irina Kusmartseva, Xiang Rong Guan, James E. Herndon, II

From the Departments of Radiology, Biostatistics and Bioinformatics, and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC

Address reprint requests to Edward F. Patz Jr, MD, Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710; e-mail: patz0002{at}mc.duke.edu

Purpose: Currently, a blood test for lung cancer does not exist. Serum biomarkers that could aid clinicians in making case management decisions would be enormously valuable. We used two proteomic platforms and a literature search to select candidate serum markers for the diagnosis of lung cancer.

Methods: We initially assayed six serum proteins, four discovered by proteomics and two previously known to be cancer associated, on a training set of sera from 100 patients (50 with a new diagnosis of lung cancer and 50 age- and sex-matched controls). Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. An independent, blinded validation set of sera from 97 patients (49 lung cancer patients and 48 matched controls) determined the accuracy of the four markers to predict which patients had lung cancer.

Results: Four serum proteins—carcinoembryonic antigen, retinol binding protein, 1-antitrypsin, and squamous cell carcinoma antigen—were collectively found to correctly classify the majority of lung cancer and control patients in the training set (sensitivity, 89.3%; specificity, 84.7%). These markers also accurately classified patients in the independent validation set (sensitivity, 77.8%; specificity, 75.4%). Remarkably, 90% of patients who fell into any one of three groupings in the CART analysis had lung cancer.

Conclusion: This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				S. Dubey and C. A. Powell Update in Lung Cancer 2007 Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 941 - 946. [Full Text] [PDF]